Which α/β ratio and half-time of repair are useful for predicting outcomes in prostate cancer?

Radiotherapy and Oncology

Volumn 97, Issue 3, 2010, Pages 462-466

  Nickers, Philippe ^a,b   Hermesse, Johanne ^a   Deneufbourg, Jean Marie ^a   Vanbelle, Sophie ^a   Lartigau, Eric ^b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b CENTRE OSCAR LAMBRET   (France)

Author keywords

ratio; Androgen deprivation therapy; Prostate cancer; Radiobiology; Radiotherapy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGED; ALPHA BETA RATIO; ARTICLE; BRACHYTHERAPY; DISEASE MARKER; EXTERNAL BEAM RADIOTHERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL PARAMETERS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE ADENOCARCINOMA; RADIATION DOSE; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; BRACHYTHERAPY; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; MALE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; TREATMENT OUTCOME;

EID: 78651512165     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2010.06.006     Document Type: Article

References (31)

1. A. Dasu Is the α/β value for prostate tumours low enough to be safely used in clinical trials? Clin Oncol 19 2007 289 301
2. E.F. Miles, and W.R. Lee Hypofractionation for prostate cancer: a critical review Semin Radiat Oncol 18 2008 41 47
3. D.J. Brenner, and E.J. Hall Fractionation and protraction for radiotherapy of prostate carcinoma Int J Radiat Oncol Biol Phys 43 1999 1095 1101
4. D.J. Brenner, A.A. Martinez, G.K. Edmundson, C. Mitchell, H.D. Thames, and E.P. Armour Direct evidence that prostate tumours show high sensitivity to fractionation (low α/β), similar to late-responding normal tissue Int J Radiat Oncol Biol Phys 52 2002 6 13
5. W.S. Williams, J.M. Taylor, and N. Liu Use of individual fraction size data from 3756 patients to directly determine the α/β ratio of prostate cancer Int J Radiat Oncol Biol Phys 68 2007 24 33
6. R. Mirabell, S.A. Roberts, E. Zubizarreta, and J.H. Hendry Dose fractionation sensitivities of low/middle/high risk cancer deduced from seven international primary institutional datasets Int J Radiat Oncol Biol Phys 75 2009 S81
7. A. Pollack, M. Buyyounouski, and E. Horwitz Hypofractionation for prostate cancer: interim results of a randomized trial Int J Radiat Oncol Biol Phys 75 2009 S81
8. J.Z. Wang, M. Guerrero, and X.A. Li How low is the α/β ratio for prostate cancer? Int J Radiat Oncol Biol Phys 55 2003 194 203
9. J.Z. Wang, and X.A. Li Impact of tumour repopulation on radiotherapy planning Int J Radiat Oncol Biol Phys 61 2005 220 227
10. A.E. Nahum, B. Mosvas, E.M. Horwitz, C.C. Strobbe, and J.D. Chapman Incorporating clinical measurements of hypoxia into tumour local control modelling of prostate cancer: implications for the α/β ratio Int J Radiat Oncol Biol Phys 57 2003 391 401
11. R. Vergis, C.M. Corbishley, and A.R. Norman Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study Lancet Oncol 9 2008 342 351
12. J. Fowler, R. Chappell, and M. Ritter Is α/β for prostate tumours really low? Int J Radiat Oncol Biol Phys 50 2001 1021 1031
13. M. Carlone, D. Wilkins, B. Nyiri, and P. Raaphorst Comparison of alpha/beta estimates from homogeneous and heterogeneous tumour control models for early stage prostate cancer Med Phys 31 2004 1176 1182
14. C. Schinkel, M. Carlone, B. Warkentin, and B.G. Fallone Analytic investigation into effect of population heterogeneity on parameter ratio estimates Int J Radiat Oncol Biol Phys 69 2007 1323 1330
15. 192Ir low dose rate brachytherapy for boosting locally advanced prostate cancers after external beam radiotherapy: a phase II trial Radiother Oncol 79 2006 329 334
16. 192Ir brachytherapy and external beam radiotherapy aiming at delivering 80-85 Gy to prostatic adenocarcinoma Radiother Oncol 55 2000 41 47
17. P. Nickers, J. Hermesse, and N. Jansen HDR or LDR in the radiation treatment of prostate cancer: identical results or toxicity rates? Radiother Oncol 83 2007 38 (S1)
18. R.G. Dale The use of small fraction numbers in high dose-rate gynaecological afterloading: some radiobiological considerations Br J Radiol 63 1990 290 294
19. E.K. Albert Harris, and A. Albert Survivorship analysis for clinical studies 1997 Dekker New York
20. M. Roach III, G. Hanks, and H. Thames Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference Int J Radiat Oncol Biol Phys 65 2006 965 974
21. D.J. D'Ambrosio, T. Li, E.M. Horwitz, D.Y. Chen, A. Pollack, and M.K. Buyyounouski Does treatment duration affect outcome after radiotherapy for prostate cancer? Int J Radiat Oncol Biol Phys 72 2008 1402 1407
22. C.A. Perez, J. Michalski, D. Mansur, and M.A. Lockett Impact of elapsed treatment time on outcome of external-beam radiation therapy for localized carcinoma of the prostate Cancer J 10 2004 349 356
23. W.D. D'Souza, and H.D. Thames Is the α/β ratio for prostate cancer low? Int J Radiat Oncol Biol Phys 52 2001 1 3
24. E.E. Yeoh, R.H. Holloway, and R.J. Fraser Hypofractionated vs conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial Int J Radiat Oncol Biol Phys 66 2006 1072 1083
25. H. Lukka, C. Hayter, and J.A. Julian Randomized trial comparing two fractionation schedules for patients with localized prostate cancer J Clin Oncol 23 2005 6132 6138
26. G. Arcangeli, B. Saracino, and S.A. Gomellini A phase III randomized study of high dose conventional vs. hypofractionated radiotherapy in patients with high risk prostate cancer Int J Radiat Oncol Biol Phys 75 2009 S79
27. S.M. Bentzen, and M.A. Ritter The α/β ratio for prostate cancer: what is it, really? Radiother Oncol 76 2005 1 3
28. P.J. Hoskin, K. Motohashi, P. Bownes, L. Bryant, and P. Ostler High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: initial results of a randomised phase three trial Radiother Oncol 84 2007 114 120
29. B.R. Pieters, D.Z. de Back, C.C.E. Koning, and A.H. Zwinderman Comparison of three radiotherapy modalities on biochemical control and overall survival for the treatment of prostate cancer: a systematic review Radiother Oncol 93 2009 168 173
30. L.Y. Khor, K. Bae, and A. Pollack COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial Lancet Oncol 8 2007 912 920
31. M. Che, M. De Silvio, and A. Pollack Prognostic value of abnormal p53 expression in locally advanced prostate cancer treated with androgen deprivation and radiotherapy: a study based on RTOG 9202 Int J Radiat Oncol Biol Phys 69 2007 1117 1123